Meanwhile, no obvious toxicity associated with the dual treatment was observed in our study, the basic safety evaluation in vivo show that combination therapy had no significant effect on the body weight and serological parameters of C57 mice (Figure S3 & Table S2).Therefore, our study provides a rationale for the clinical use of CDK4/6is and PD-1 blockade in ovarian cancer patients. This evidence concerns the gene CDK4 and ovarian cancer.